Literature DB >> 25815291

A new proteomic test could guide treatment decision in second-line therapy for patients with EGFR unselected non-small cell lung cancer?

Francesca Mazzoni1, Paolo Petreni1, Alice Lunghi1.   

Abstract

Entities:  

Year:  2015        PMID： 25815291      PMCID： PMC4356860          DOI： 10.3978/j.issn.2305-5839.2015.01.03

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  15 in total

1.  Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

Authors:  Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenas; Skaidrius Miliauskas; Alexandru Calin Grigorescu; Carina Hillenbach; Hrefna Kristin Johannsdottir; Barbara Klughammer; Emilio Esteban Gonzalez
Journal:  Lancet Oncol       Date:  2012-01-24       Impact factor: 41.316

2.  Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

Authors:  Tomoya Kawaguchi; Masahiko Ando; Kazuhiro Asami; Yoshio Okano; Masaaki Fukuda; Hideyuki Nakagawa; Hidenori Ibata; Toshiyuki Kozuki; Takeo Endo; Atsuhisa Tamura; Mitsuhiro Kamimura; Kazuhiro Sakamoto; Michihiro Yoshimi; Yoshifumi Soejima; Yoshio Tomizawa; Shun-ichi Isa; Minoru Takada; Hideo Saka; Akihito Kubo
Journal:  J Clin Oncol       Date:  2014-05-19       Impact factor: 44.544

3.  Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.

Authors:  David P Carbone; Keyue Ding; Heinrich Roder; Julia Grigorieva; Joanna Roder; Ming-Sound Tsao; Lesley Seymour; Frances A Shepherd
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

4.  Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Authors:  Marina Chiara Garassino; Olga Martelli; Massimo Broggini; Gabriella Farina; Silvio Veronese; Eliana Rulli; Filippo Bianchi; Anna Bettini; Flavia Longo; Luca Moscetti; Maurizio Tomirotti; Mirko Marabese; Monica Ganzinelli; Calogero Lauricella; Roberto Labianca; Irene Floriani; Giuseppe Giaccone; Valter Torri; Alberto Scanni; Silvia Marsoni
Journal:  Lancet Oncol       Date:  2013-07-22       Impact factor: 41.316

5.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

Authors:  F A Shepherd; J Dancey; R Ramlau; K Mattson; R Gralla; M O'Rourke; N Levitan; L Gressot; M Vincent; R Burkes; S Coughlin; Y Kim; J Berille
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

6.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Authors:  Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

7.  A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.

Authors:  Thomas E Stinchcombe; Joanna Roder; Amy H Peterman; Julia Grigorieva; Carrie B Lee; Dominic T Moore; Mark A Socinski
Journal:  J Thorac Oncol       Date:  2013-04       Impact factor: 15.609

8.  Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

Authors:  Fumiko Taguchi; Benjamin Solomon; Vanesa Gregorc; Heinrich Roder; Robert Gray; Kazuo Kasahara; Makoto Nishio; Julie Brahmer; Anna Spreafico; Vienna Ludovini; Pierre P Massion; Rafal Dziadziuszko; Joan Schiller; Julia Grigorieva; Maxim Tsypin; Stephen W Hunsucker; Richard Caprioli; Mark W Duncan; Fred R Hirsch; Paul A Bunn; David P Carbone
Journal:  J Natl Cancer Inst       Date:  2007-06-06       Impact factor: 13.506

9.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Authors:  Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard
Journal:  Lancet       Date:  2008-11-22       Impact factor: 79.321

10.  Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.

Authors:  Vanesa Gregorc; Silvia Novello; Chiara Lazzari; Sandro Barni; Michele Aieta; Manlio Mencoboni; Francesco Grossi; Tommaso De Pas; Filippo de Marinis; Alessandra Bearz; Irene Floriani; Valter Torri; Alessandra Bulotta; Angela Cattaneo; Julia Grigorieva; Maxim Tsypin; Joanna Roder; Claudio Doglioni; Matteo Giaj Levra; Fausto Petrelli; Silvia Foti; Mariagrazia Viganò; Angela Bachi; Heinrich Roder
Journal:  Lancet Oncol       Date:  2014-05-13       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.